8.01

1.60% -0.13

Iovance Biotherapeutics Inc (IOVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt IOVA? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$8.14

Offen:

$8.15

24-Stunden-Volumen:

763.05K

Relative Volume:

0.13

Marktkapitalisierung:

$2.48B

Einnahmen:

$32.77M

Nettoeinkommen (Verlust:

$-440.22M

KGV:

-3.5759

EPS:

-2.24

Netto-Cashflow:

$-400.48M

1W Leistung:

-6.75%

1M Leistung:

-19.25%

6M Leistung:

-22.38%

1J Leistung:

+54.93%

1-Tages-Spanne:

$7.98

$8.23

1-Wochen-Bereich:

$8.0218

$8.70

52-Wochen-Spanne:

$5.24

$18.33

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Firmenname

Iovance Biotherapeutics Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

(650) 260-7120

Adresse

825 INDUSTRIAL ROAD, SAN CARLOS

Mitarbeiter

557

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

IOVA's Discussions on Twitter

Vergleichen Sie IOVA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IOVA	8.015	2.48B	32.77M	-440.22M	-400.48M	-2.24
VRTX	445.81	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	735.95	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	584.00	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.73	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.25	24.49B	3.30B	-501.07M	1.03B	11.54

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-11-20	Eingeleitet	Goldman	Buy
2023-09-18	Bestätigt	Barclays	Overweight
2023-05-30	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-27	Fortgesetzt	Wells Fargo	Equal Weight
2023-01-27	Hochstufung	Piper Sandler	Neutral → Overweight
2022-12-09	Herabstufung	Goldman	Buy → Neutral
2022-10-31	Eingeleitet	Guggenheim	Neutral
2022-08-18	Fortgesetzt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Stifel	Hold → Buy
2021-12-07	Fortgesetzt	Cowen	Outperform
2021-06-10	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Herabstufung	Piper Sandler	Overweight → Neutral
2021-05-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Herabstufung	Stifel	Buy → Hold
2021-05-03	Eingeleitet	Truist	Buy
2021-04-16	Eingeleitet	Goldman	Buy
2021-03-08	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-10-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-22	Eingeleitet	Mizuho	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-02-26	Bestätigt	H.C. Wainwright	Buy
2020-02-26	Bestätigt	Oppenheimer	Outperform
2019-12-18	Eingeleitet	JMP Securities	Mkt Outperform
2019-10-01	Eingeleitet	Stifel	Buy
2019-04-29	Eingeleitet	Piper Jaffray	Overweight
2019-02-28	Bestätigt	Chardan Capital Markets	Buy
2019-02-07	Eingeleitet	Robert W. Baird	Outperform
2018-12-31	Fortgesetzt	B. Riley FBR	Buy
2018-07-06	Bestätigt	Chardan Capital Markets	Buy
2018-04-10	Hochstufung	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Bestätigt	B. Riley FBR, Inc.	Neutral
2018-02-23	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Bestätigt	H.C. Wainwright	Buy
2017-11-01	Bestätigt	B. Riley FBR, Inc.	Buy

Alle ansehen

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

Nov 19, 2024

Long Term Trading Analysis for (IOVA) - Stock Traders Daily

Nov 19, 2024

Nov 15, 2024

Perceptive Advisors LLC's Strategic Acquisition in Iovance Bioth - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Iovance Biotherapeutics director Maynard sells $503k in stock - Investing.com

Nov 14, 2024

IOVA (Iovance Biotherapeutics) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Nov 13, 2024

Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Australia

Nov 13, 2024

Nov 12, 2024

Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 12, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Principal Financial Group Inc. - MarketBeat

Nov 12, 2024

Nov 11, 2024

Iovance Biotherapeutics Q3: A Beat, But A SelloffNow A Buy Opportunity - Seeking Alpha

Nov 11, 2024

HC Wainwright Has Positive Outlook for IOVA FY2027 Earnings - MarketBeat

Nov 11, 2024

Nov 09, 2024

Earnings call: Iovance reported a third-quarter product revenue of $58.6 million - Investing.com India

Nov 09, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance UK

Nov 09, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line - MSN

Nov 08, 2024

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap DownTime to Sell? - MarketBeat

Nov 08, 2024